13F Holdings
中文EN

GCTK Glucotrack, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1506983 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.4%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-620.6%
ROA-272.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets216.5%
Debt / equity—
Current ratio0.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$9.81M$9.50M$4.70M$1.97M$1.81M
SG&A expense$6.28M$5.05M$2.28M$2.46M$2.09M
Operating income-$16.09M-$14.55M-$7.10M-$4.43M-$4.04M
Interest expense—$44,000———
Net income-$19.39M-$22.60M-$7.10M-$4.43M-$4.07M
EBITDA-$16.05M-$14.51M-$7.09M-$4.41M-$4.00M
EPS (basic)31.224,106.0034.180.290.26
EPS (diluted)31.224,106.0034.180.290.26
Weighted avg. shares (diluted)621,0945,503207,60315.47M15.45B
Balance sheet
Cash & equivalents$7.38M$5.62M$4.49M$2.31M$6.11M
Inventory————$321,000
Current assets$7.67M$5.77M$4.87M$2.38M$6.11M
PP&E, net$138,000$95,000$27,000$40,000$69,000
Total assets$7.84M$5.93M$4.91M$2.44M$6.26M
Current liabilities$4.77M$1.27M$1.51M$1.01M$883,000
Total liabilities$5.01M$18.93M$1.71M$1.21M$1.11M
Shareholders' equity$2.83M-$13.00M$3.20M$1.23M$5.16M
Shares outstanding910,68813,409208,91415.50M15.47M
Cash flow statement
Operating cash flow-$15.24M-$12.49M-$6.56M-$3.73M-$3.77M
Capital expenditure$96,000$104,000—$1,000$5,000
Free cash flow-$15.34M-$12.59M—-$3.73M-$3.77M
Investing cash flow-$96,000-$104,000—$1,000-$1,000
Financing cash flow$17.04M$13.74M$8.73M——
Depreciation & amortization$42,000$36,000$13,000$23,000$42,000
Stock-based compensation$211,000$173,000$281,000$439,000$223,000

Free plan shows the latest 5 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.